Novo Nordisk stock heads into the open after a 2.3% slide

At the close on September 8, 2026, Novo Nordisk stock finished lower on Nasdaq Copenhagen, dropping about 2.3% with heavy volume as its US ADR also declined. Today, investors watch Novo Nordisk stock against a muted European equity backdrop.

Novo Nordisk stock closed at DKK 292.00 on Nasdaq Copenhagen on September 8, 2026, down 2.32% from the prior session. Per exchange data compiled by Investing.com, the shares traded between DKK 291.60 and DKK 298.20 during the day on volume of about 3.89 million shares, marking an active session for the Danish drugmaker.

September 8, 2026 in numbers

Novo Nordisk A/S (ISIN DK0060534915) saw its Copenhagen-listed shares retreat on September 8, 2026 as they moved from a prior close of DKK 298.95 to a finish at DKK 292.00, with the intraday low near DKK 291.60 and high around DKK 298.20 according to historical quote data from Investing.com for that session. The same day, its US-listed ADR NVO was reported around USD 45.16 after a 3.1% drop, highlighting that the weakness extended across both European and US trading venues as noted by valuation analysis at GuruFocus. While Denmark is not part of the STOXX 600 calculation, the broader European equity tone on September 8, 2026 was subdued, with the pan-European STOXX 600 index marginally lower at about 649.6 points as reported by The Business Times, offering a cautious backdrop for regional healthcare names. In valuation terms, NVO was trading significantly below several intrinsic value estimates, with GF Value metrics pointing to an implied fair value that was more than 50% above the prevailing ADR price, according to analysis highlighted by GuruFocus, even as the immediate session on September 8, 2026 reflected selling pressure.

Market cues for today

Today, September 9, 2026, Novo Nordisk trades without a scheduled earnings release, with the next earnings date for its US ADR indicated as November 5, 2026 in the Nasdaq event overview seen on CNBC. Broader European equities were described as muted on September 8, 2026 amid higher crude prices and sector-specific volatility, according to WKZO, a setting that may continue to shape sentiment toward large-cap European healthcare stocks today. Against that backdrop, investors can weigh Novo Nordisk stock alongside regional indices after its recent decline, with attention on how the shares trade into today’s session following the notable 2.32% pullback on September 8, 2026.